SOPHiA GENETICS reports 27% revenue growth and raises guidance

The AI-driven precision-medicine company reported Q2 revenue of US$23.3 million, up 27% year on year; a US$22.4 million net loss; an adjusted EBITDA loss of US$8.8 million; 115,000 SOPHiA DDM analyses; and 542 core genomics customers. It raised 2026 revenue guidance to US$94–96 million. A Form 6-K supports the results. Adjusted measures are non-IFRS and the company itself details their limitations.

Why it matters: this is measurable commercial adoption of multimodal/genomic AI, but revenue growth and analysis volume do not establish clinical benefit. Buyers should inspect regulatory status, validation, local calibration and total workflow cost.